There are currently 45 active clinical trials seeking participants for Migraine research studies. The states with the highest number of trials for Autism participants are Florida, California, Texas and New York.
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172
Recruiting
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/16/2024
Locations: Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut +36 locations
Conditions: Migraine
Register for Updates
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
NCT04930887
Recruiting
Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial pain. This study would be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion. We aim to investigate whether the administration of Exparel (Bupivacaine) to the lateral nasal wall may pos... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/16/2024
Locations: Peter H Hwang, Stanford, California
Conditions: Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/16/2024
Locations: Central Research Associates, Birmingham, Alabama +161 locations
Conditions: Migraine
Register for Updates
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928
Recruiting
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 2 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2024
Locations: Accellacare of Charleston, Mount Pleasant, South Carolina
Conditions: Migraine
Register for Updates
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/15/2024
Locations: Central Research Associates, Birmingham, Alabama +162 locations
Conditions: Migraine
Register for Updates
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
NCT05452239
Recruiting
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with h... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2024
Locations: Clinical Research of Central Florida - ClinEdge - PPDS, Winter Haven, Florida +74 locations
Conditions: Migraine, Medication Overuse Headache
Register for Updates
Treatment for Migraine and Mood RCT
NCT05576467
Recruiting
The researchers propose a three-arm pilot study of Mindfulness-Based Cognitive Therapy (MBCT) delivered via telephone (Telephone), video (Video) or online education modules (Online).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Migraine, Depressive Symptoms
Register for Updates
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
NCT05158894
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing or pulsating headache on one side of the head of moderate to severe pain intensity. The purpose of this study is to evaluate fetal, maternal, and infant outcomes through 12 months of age among women exposed to Ubrelvy or Qulipta during pregnancy, as well as in 2 comparator groups. Ubrelvy (ubrogepant) and Qulipta (atogepant) are approved drugs for the acute treatment of migraine in adults. Approximately 6... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Iqvia /Id# 244683, Durham, North Carolina
Conditions: Migraine
Register for Updates
Mind Body Balance for Pediatric Migraine
NCT04715685
Recruiting
This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
03/07/2024
Locations: University of Colorado/Children's Hospital Colorado, Aurora, Colorado +1 locations
Conditions: Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Register for Updates
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age
NCT04464707
Recruiting
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical out... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/28/2024
Locations: Teva Investigational Site 14281, Little Rock, Arkansas +89 locations
Conditions: Migraine
Register for Updates
NYU Langone Health Headache Center Learning Migraine Self-Management Techniques Study
NCT06077812
Recruiting
The investigators aim to determine the feasibility of a migraine self-management program.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/26/2024
Locations: NYU Langone Health, New York, New York
Conditions: Migraine
Register for Updates
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
NCT04530110
Recruiting
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/22/2024
Locations: Teva Investigational Site 14319, Aurora, Colorado +69 locations
Conditions: Migraine
Register for Updates